ORM-5029 targets HER2, a protein often overexpressed in breast, ovarian, and gastric cancers. This first-in-class antibody-drug conjugate (ADC) offers a powerful and precise treatment option. It pairs a HER2-targeting antibody with a potent protein degrader (SMol006) to deliver precise and effective cancer treatment.
Key Features
- Target-Specific: Focuses on HER2-expressing tumor cells for precise treatment.
- Advanced Mechanism: Combines tumor-targeting antibodies with a protein degrader to disrupt cancer cell processes.
- Potent Payload: Delivers SMol006, which blocks protein synthesis, leading to cancer cell death.
Applications
- Breast Cancer: Potentially effective for HER2-positive breast cancer, including resistant cases.
- Gastric and Ovarian Cancer: Offers a targeted option for HER2-overexpressing tumors.
ORM-5029 is undergoing clinical trials to assess its safety and effectiveness in HER2-expressing advanced solid tumors. It represents an innovative approach to targeted cancer therapy.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.